EMD-31624

Single-particle
3.25 Å
EMD-31624 Deposition: 04/08/2021
Map released: 27/04/2022
Last modified: 30/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-31624

Cryo-EM structure of South African (B.1.351) SARS-CoV-2 spike glycoprotein in complex with two T6 Fab

EMD-31624

Single-particle
3.25 Å
EMD-31624 Deposition: 04/08/2021
Map released: 27/04/2022
Last modified: 30/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Homo sapiens, Severe acute respiratory syndrome coronavirus 2, Human immunodeficiency virus 1
Sample: S protein of South African (B.1.351) SARS-CoV-2 spike in complex with T6 Fab
Fitted models: 7fjn (Avg. Q-score: 0.27)

Deposition Authors: Wang X, Zhang L, Zhang S, Liang Q
RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants.
PUBMED: 35291264
DOI: doi:10.1016/j.isci.2022.104043
ISSN: 2589-0042
Abstract:
With the rapid emergence and spread of SARS-CoV-2 variants, development of vaccines with broad and potent protectivity has become a global priority. Here, we designed a lipid nanoparticle-encapsulated, nucleoside-unmodified mRNA (mRNA-LNP) vaccine encoding the trimerized receptor-binding domain (RBD trimer) and showed its robust capability in inducing broad and protective immune responses against wild-type and major variants of concern (VOCs) in the mouse model of SARS-CoV-2 infection. The protectivity was correlated with RBD-specific B cell responses especially the long-lived plasma B cells in bone marrow, strong ability in triggering BCR clustering, and downstream signaling. Monoclonal antibodies isolated from vaccinated animals demonstrated broad and potent neutralizing activity against VOCs tested. Structure analysis of one representative antibody identified a novel epitope with a high degree of conservation among different variants. Collectively, these results demonstrate that the RBD trimer mRNA vaccine serves as a promising vaccine candidate against SARS-CoV-2 variants and beyond.